Testing effectiveness (Phase 2)Study completedNCT03616834What this trial is testingTomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor TherapyWho this might be right forSolid Tumors Effector Therapeutics 39
Not applicableUnknownNCT03683407What this trial is testingEffect of Chemotherapy on TMB in NSCLCWho this might be right forChemotherapy EffectImmunotherapyTumor Mutation Burden+1 more Baodong Qin 30
Testing effectiveness (Phase 2)UnknownNCT03994744What this trial is testingAssessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLCWho this might be right forSmall-cell Lung CancerSmall Cell Lung CarcinomaSmall Cell Lung Cancer Recurrent+1 more Hunan Cancer Hospital 68
Testing effectiveness (Phase 2)Study completedNCT02798406What this trial is testingCombination Adenovirus + Pembrolizumab to Trigger Immune Virus EffectsWho this might be right forBrain CancerBrain NeoplasmGlioma+8 more DNAtrix, Inc. 49
Testing effectiveness (Phase 2)Study completedNCT03680521What this trial is testingNeoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell CarcinomaWho this might be right forClear Cell Renal Cell Carcinoma Mirati Therapeutics Inc. 25
Large-scale testing (Phase 3)Not Yet RecruitingNCT07790380What this trial is testingFH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy.Who this might be right forLocally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy Jiangsu HengRui Medicine Co., Ltd. 480
Post-approval studies (Phase 4)Looking for participantsNCT07744698What this trial is testingMetronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)Who this might be right forSquamous Non-Small Cell Lung Cancer sqNSCLCExtensive-stage Small Cell Lung Cancer (ES-SCLC) Anhui Provincial Cancer Hospital 107
Testing effectiveness (Phase 2)Looking for participantsNCT05431270What this trial is testingDose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)Who this might be right forNon Small Cell Lung CancerPancreatic Ductal Adenocarcinoma Phanes Therapeutics 40
Not applicableUnknownNCT04203095What this trial is testingChromosomal Instability as a Surrogate Biomarker of Drug Resistance in Immunotherapy for Lung Cancer PatientsWho this might be right forLung Cancer Shanghai Pulmonary Hospital, Shanghai, China 40
Early research (Phase 1)Ended earlyNCT03549000What this trial is testingA Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.Who this might be right forNon-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer (TNBC)Pancreatic Ductal Adenocarcinoma (PDAC)+4 more Novartis Pharmaceuticals 127
Early research (Phase 1)Looking for participantsNCT06411691What this trial is testingKRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal CancerWho this might be right forColorectal CancerPancreatic Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 54
Testing effectiveness (Phase 2)Study completedNCT03085914What this trial is testingEpacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)Who this might be right forSolid Tumor Incyte Corporation 70
Testing effectiveness (Phase 2)WithdrawnNCT02535078What this trial is testingPhase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous MelanomaWho this might be right forMalignant Melanoma Immunocore Ltd
Large-scale testing (Phase 3)Looking for participantsNCT04966481What this trial is testingPalbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 InhibitorWho this might be right forHPV-unrelated Head and Neck Squamous Cell Carcinoma Washington University School of Medicine 81
Not applicableStudy completedNCT04609930What this trial is testingImpact of Immune Checkpoint Inhibitor Therapy on Type 2 InflammationWho this might be right forPatients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies University Hospital, Montpellier 143
Not applicableLooking for participantsNCT06635954What this trial is testingA Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.Who this might be right forCancerImmunotherapyPD-1+2 more Oxford Biodynamics Inc. 2,000
Testing effectiveness (Phase 2)UnknownNCT04239443What this trial is testingClinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine CancerWho this might be right forAdvanced Non Small Cell Lung CancerUterine CancerSoft Tissue Sarcoma Hunan Cancer Hospital 120
Early research (Phase 1)Active Not RecruitingNCT05878691What this trial is testingGRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.Who this might be right forAdvanced Solid TumorLymphoma Glenmark Specialty S.A. 320
Testing effectiveness (Phase 2)Ended earlyNCT03116529What this trial is testingNeoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue SarcomaWho this might be right forSoft Tissue Sarcoma University of Maryland, Baltimore 22
Testing effectiveness (Phase 2)Study completedNCT04796194What this trial is testingIntratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced MelanomaWho this might be right forAdvanced Melanoma Lytix Biopharma AS 23